MIT 45 Gold Liquid Kratom Extract 15ml
Description
Description
Ingredients
Ingredients
Suggested Use
Suggested Use
Shipping & Return
Shipping & Return
SHIPPING POLICY: We ship across all 50 U.S. states (excluding restricted states) using USPS or UPS, with delivery options selected at checkout. Orders are typically processed within 1–3 business days after payment, unless it’s a pre-sale item or there’s a rare delay—if so, we’ll notify you via email. If your order arrives damaged or incomplete, please contact us within 7 days of delivery. Learn more →
RETURN POLICY: Not satisfied with your order? You can request a return within 7 days of delivery, and items must be sent back within 21 days with prior authorization. Unopened products are eligible for a full refund, while opened items may qualify for partial refunds in select cases. Once we receive and inspect your return, refunds or replacements are processed within 5–10 business days. Learn more →
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.
Key Benefits


About This Product
MIT 45 Gold is the flagship of the MIT 45 line and one of the most recognized SKUs in the kratom extract category. It is sold direct by the manufacturer at $17.99, though street pricing has fallen well below that, frequently under $11.
MIT 45 markets Gold on focus, clarity, and productivity, aimed at what they describe as entrepreneurs and athletes. Their tagline for it is The Gold Standard of Kratom.
Product Origin. MIT 45 is a Utah-based extract manufacturer and a listed American Kratom Association GMP Qualified Vendor. Water-based extraction, proprietary multi-step purification. Current lots are tested by Cambium Analytica in Traverse City, Michigan, an ISO/IEC 17025:2017 accredited laboratory.
One caution on lab data for this SKU specifically: several resellers publish a figure of 249mg mitragynine across three 83mg servings for MIT 45 Gold. That number is roughly double both the manufacturer's claim and the published certificate. It appears to be legacy data from an older formulation. Ignore it.
MIT 45 has an active class action against it in the Southern District of California (B.D. et al. v. MIT45, Inc., 3:24-cv-00499) concerning disclosure of dependency risk on concentrated extracts. The court largely denied MIT 45's motion to dismiss in July 2024. The case is ongoing.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Discover more in our FAQ
Have any concerns? Shoot our team an email & we’ll get back to you ASAP


